BAY 57-1293 | 2556

BAY 57-1293 is a potent helicase primase inhibitor. It inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. BAY 57-1293 has been shown to be a more effective agent than acyclovir (Cat. No. 2200) for treating Alzjeimer’s Disease (AD) by decreasing Aβ and P-tau formation.

BAY 57-1293 is a potent helicase primase inhibitor. It inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections.

2556 | BAY 57-1293 DataSheet

Alternate Name/Synonyms: N-methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 348086-71-5

Structure Available?: Y

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₈H₁₈N₄O₃S₂

Molecular Weight: 402.49

Cell-Permeable?: Yes

Purity: ≥95% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent helicase primase inhibitor

MDL Number: N/A

PubChem CID: 491941

SMILES: CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N

InChi: InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)

InChi Key: IVZKZONQVYTCKC-UHFFFAOYSA-N